交银国际每日晨报-20260323

Group 1: Core Insights - The CXO sector in China is experiencing a recovery in demand and a reshaping of its landscape, driven by multiple favorable factors since 2025, leading to a sustained market rebound [1][2] - The sector's valuation multiples are deemed reasonable, with potential for upward revisions in profit forecasts for 2026-27 due to better-than-expected new orders and backlog indicators [1][2] - Emerging business segments are expected to drive structural upgrades in the industry, leading to a long-term increase in valuation levels [1][2] Group 2: Future Development Trends - Four key trends are identified for future development: expansion, upgrading, integration, and AI in drug development [2] - The demand for R&D and production outsourcing is expanding, pushing the industry towards growth, while pharmaceutical companies are increasingly focused on technological advancements and global supply chain resilience [2] - The trend of Chinese companies going abroad for business development (BD) is anticipated to create long-term opportunities, although it may also intensify industry differentiation [2] - Leading companies are expected to pursue various forms of integration, putting pressure on smaller firms lacking forward-looking strategies [2] - AI in drug discovery is projected to reach a developmental turning point in 2026, with its value in drug discovery expected to be further validated [2] Group 3: Market Outlook and Recommendations - The report recommends focusing on high-quality leaders in high-growth sectors, emphasizing growth potential, core capabilities, profitability, order visibility, geopolitical risk exposure, and valuation upside [3] - Specific companies highlighted for investment include WuXi AppTec, with initial coverage on Kelun Pharmaceutical and Kanglong Chemical [3]